Pub Date : 2018-01-01DOI: 10.22259/2639-3581.0101002
C. Tsompos, C. Panoulis, K. Toutouzas, A. Triantafyllou, C. Zografos, A. Papalois, K. Tsarea, M. Karamperi
Aim: This study calculated the hypoglucemic capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the hypoglucemic influence, after the respective drug usage in an induced hypoxia reoxygenation animal experiment. Materials and Methods: The 2 main experimental endpoints at which the glucose (Gl) levels were evaluated was the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration. Results: The first preliminary study of Epo presented a non significant hypoglucemic effect by 0.84%+1.12% (p-value=0.4430). The second preliminary study of U-74389G presented a significant hypoglucemic effect by 3.94%+1.06% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 4.660603-fold more hypoglucemic potency than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G enhance the acute hypoglucemic properties presenting 4.660603-fold more intentive hypoglucemia than Epo (p-value=0.0000).
{"title":"Comparison of the Hypoglucemic Effects of Erythropoietin and U-74389G on Glucose Levels","authors":"C. Tsompos, C. Panoulis, K. Toutouzas, A. Triantafyllou, C. Zografos, A. Papalois, K. Tsarea, M. Karamperi","doi":"10.22259/2639-3581.0101002","DOIUrl":"https://doi.org/10.22259/2639-3581.0101002","url":null,"abstract":"Aim: This study calculated the hypoglucemic capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the hypoglucemic influence, after the respective drug usage in an induced hypoxia reoxygenation animal experiment. Materials and Methods: The 2 main experimental endpoints at which the glucose (Gl) levels were evaluated was the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration. Results: The first preliminary study of Epo presented a non significant hypoglucemic effect by 0.84%+1.12% (p-value=0.4430). The second preliminary study of U-74389G presented a significant hypoglucemic effect by 3.94%+1.06% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 4.660603-fold more hypoglucemic potency than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G enhance the acute hypoglucemic properties presenting 4.660603-fold more intentive hypoglucemia than Epo (p-value=0.0000).","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.22259/2639-3581.0101005
Onwurah O.W, Onyenekwe C. C, Ifeanyichukwu M, Ezeugwunne I. P, Igweze Z. G, Apakama A.I, Amilo G.I, Okosa M.C
{"title":"Evaluation of Some Haematological Parameters among Different Tribes Residing in Nnewi, Anambra State, Nigeria","authors":"Onwurah O.W, Onyenekwe C. C, Ifeanyichukwu M, Ezeugwunne I. P, Igweze Z. G, Apakama A.I, Amilo G.I, Okosa M.C","doi":"10.22259/2639-3581.0101005","DOIUrl":"https://doi.org/10.22259/2639-3581.0101005","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：